EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cholesterol Pathway Gene Variants and Reduced Keratinocyte Cholesterol Support a Final Common Druggable Pathway in Hyperproliferative Inflammatory Skin Diseases

Melissa Riachi, Dale Bryant, James Ellis, Connor Hughes, Satyamaanasa Polubothu, Ignacio Del Valle Torres, Aimie Sauvadet, Nicole Knöpfel, Noreen Muwanga-Nanyonjo, Sara Barberan Martin, Alicia Bruzos, Gavin Kelly und 16 weitere

Journal of Investigative Dermatology · 2025-11 · 145 (11) · 2745-2752.e7

DOI: 10.1016/j.jid.2025.02.157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Melissa Riachi und 27 weiteren Autor:innen. Beteiligte Einrichtung: Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL GOS Institute of…. Hauptthemen laut MEDLINE: Keratinocytes, Cholesterol, Psoriasis, Skin Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University College London, NIHR, Great Ormond Street Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperproliferative inflammatory skin disease (HISD) is frequently seen in rare monogenic diseases of cholesterol metabolism and responds to topical cholesterol/statin. We hypothesized that aberrant cholesterol metabolism within keratinocytes could be important in HISD more generally, driven by either immunological or lipid pathway genetic variation. Whereas other epidermal lipids have been well-characterized in HISDs, cholesterol and its metabolites have not. In this study, using comprehensive 2-dimensional gas chromatography 3-dimensional mass spectrometry, we found that primary keratinocytes from diverse monogenic HISDs (inflammatory linear verrucous epidermal nevi, n = 14; CHILD [congenital hemidysplasia with ichthyosiform erythroderma and limb defects] syndrome, n = 2) and from plaque psoriasis (n = 2) demonstrate significantly reduced mean cholesterol across all patient groups compared with those across the controls. This striking abnormality appears causally implicated because treatment in vitro with cholesterol and statin rescued the cellular hyperproliferation. Using SNPsea and burden analysis of large international psoriasis cohorts, we went on to show that GWAS hits were significantly enriched in proximity to genes encoding lipid metabolic pathways and that rare variants in lipid metabolic pathway genes were significantly enriched in patients with psoriasis. These data identify a final common pathway of aberrant keratinocyte cholesterol metabolism in HISD, which should be drugged topically to avoid first-pass metabolism. In parallel, we implicate genetic variation in lipid pathway genes in psoriasis susceptibility, potentially explaining the comorbidity of abnormal serum lipid profile and psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratinocytesCholesterolPsoriasisSkin DiseasesHumansMaleFemaleGenome-Wide Association StudyCells, CulturedHydroxymethylglutaryl-CoA Reductase InhibitorsChildLipid MetabolismCell ProliferationPolymorphism, Single NucleotideGas Chromatography-Mass SpectrometryAdult

Stichwörter der Autor:innen

CholesterolKeratinocytePsoriasisStatinTherapy

Substanzen

CholesterolHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL GOS Institute of Child Health, London, United Kingdom.
  • Metabolomics Science Technology Platform, The Francis Crick Institute, London, United Kingdom.
  • Genetics and Genomic Medicine, UCL GOS Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond St Hospital for Children, London, United Kingdom.
  • Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL GOS Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great O…
  • Bioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.
  • Food Science, Research Center in Food and Development A.C., Hermosillo, Mexico.

Förderung

  • University College London
  • NIHR
  • Great Ormond Street Hospital Charity
  • University of Southampton

Zitieren

APA

Riachi, M., Bryant, D., Ellis, J., Hughes, C., Polubothu, S., Del Valle Torres, I., Sauvadet, A., Knöpfel, N., Muwanga-Nanyonjo, N., Martin, S. B., Bruzos, A., Kelly, G., Calvani, E., Palma-Duran, S. A., Silva Dos Santos, M., Chaloner, C., Khalil, Y., Clayton, P., Mills, P., …, & Kinsler, V. A. (2025). Cholesterol Pathway Gene Variants and Reduced Keratinocyte Cholesterol Support a Final Common Druggable Pathway in Hyperproliferative Inflammatory Skin Diseases. Journal of Investigative Dermatology, 145(11), 2745-2752.e7. https://doi.org/10.1016/j.jid.2025.02.157

Vancouver

Riachi M, Bryant D, Ellis J, Hughes C, Polubothu S, Del Valle Torres I, et al. Cholesterol Pathway Gene Variants and Reduced Keratinocyte Cholesterol Support a Final Common Druggable Pathway in Hyperproliferative Inflammatory Skin Diseases. Journal of Investigative Dermatology. 2025;145(11):2745-2752.e7. doi:10.1016/j.jid.2025.02.157

BibTeX
@article{Riachi2025,
  author = {Riachi, Melissa and Bryant, Dale and Ellis, James and Hughes, Connor and Polubothu, Satyamaanasa and Del Valle Torres, Ignacio and Sauvadet, Aimie and Knöpfel, Nicole and Muwanga-Nanyonjo, Noreen and Martin, Sara Barberan and Bruzos, Alicia and Kelly, Gavin and Calvani, Enrica and Palma-Duran, Susana A and Silva Dos Santos, Mariana and Chaloner, Charlotte and Khalil, Youssef and Clayton, Peter and Mills, Philippa and Bulstrode, Neil and Dand, Nick and Di, Wei-Li and Barral, Patricia and Simpson, Michael A and Barker, Jonathan and Lee, James C and Macrae, James and Kinsler, Veronica A},
  title = {Cholesterol Pathway Gene Variants and Reduced Keratinocyte Cholesterol Support a Final Common Druggable Pathway in Hyperproliferative Inflammatory Skin Diseases},
  journal = {Journal of Investigative Dermatology},
  year = {2025},
  volume = {145},
  number = {11},
  pages = {2745--2752.e7},
  doi = {10.1016/j.jid.2025.02.157}
}
Kostenlos starten →